What is Marinus Pharmaceuticals?
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of ganaxolone, a therapeutic agent designed to address epilepsy and neuropsychiatric disorders. Ganaxolone operates as a positive allosteric modulator of GABAA, targeting a well-established pathway in the brain known for its anti-seizure, anti-depressant, and anti-anxiety effects. The company is pursuing multiple dosage forms, including intravenous, capsule, and liquid formulations, to cater to both adult and pediatric patient populations across acute and chronic care settings. Marinus has advanced its pipeline with pivotal studies in children suffering from CDD, a rare form of epilepsy, and is also investigating ganaxolone for postpartum depression and refractory status epilepticus.
How much funding has Marinus Pharmaceuticals raised?
Marinus Pharmaceuticals has raised a total of $360.2M across 11 funding rounds:
Series C
$21M
Stock Offering
$41.3M
Stock Offering
$27.7M
Stock Offering
$40.3M
Stock Offering
$45M
Stock Offering
$70M
Other Financing Round
$30M
Other Financing Round
$32.5M
Series C (2013): $21M featuring Sofinnova Ventures, Foundation Medicine, Canaan Partners, Domain Associates, and RusnanoMedInvest
Stock Issuance/Offering (2014): $41.3M backed by Undisclosed
Stock Issuance/Offering (2015): $27.7M with participation from Undisclosed
Stock Issuance/Offering (2017): $40.3M led by Bain Capital
Stock Issuance/Offering (2018): $45M supported by Undisclosed
Stock Issuance/Offering (2019): $70M featuring Undisclosed
Other Financing Round (2022): $30M backed by Oaktree
Other Financing Round (2022): $32.5M with participation from Morgan Stanley and H.C. Wainwright & Co.
Key Investors in Marinus Pharmaceuticals
Morgan Stanley
Morgan Stanley is a leading global financial services firm providing a wide range of investment banking, securities, wealth management, and investment management services. The firm serves clients worldwide, including corporations, governments, institutions, and individuals.
H.C. Wainwright & Co.
H.C. Wainwright & Co. provides financial services in the scope of investment banking, including financial advisory, liquidity trading, and financial research. The company is headquartered in New York City.
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, known for its opportunistic, value-oriented, and risk-controlled approach across credit, equity, and real estate markets.
What's next for Marinus Pharmaceuticals?
The substantial enterprise-level funding indicates a critical growth phase for Marinus Pharmaceuticals, likely aimed at advancing clinical trials, expanding manufacturing capabilities, and preparing for potential commercialization. The company's strategic focus on ganaxolone, with its novel mechanism of action and broad therapeutic potential, positions it to address significant unmet needs in neurological and psychiatric care. Future developments will likely center on regulatory submissions and market access strategies, leveraging the recent capital infusion to drive its mission forward.
See full Marinus Pharmaceuticals company page
